This HTML5 document contains 37 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

PrefixNamespace IRI
n15http://hub.abes.fr/springer/periodical/10620/1994/volume_39/issue_12/
marcrelhttp://id.loc.gov/vocabulary/relators/
vivohttp://vivoweb.org/ontology/core#
dctermshttp://purl.org/dc/terms/
n12http://orcid.org/0000-0001-9479-5307#
n4http://hub.abes.fr/springer/periodical/10620/1994/volume_39/issue_12/B947C239FA9D2014E053120B220ACB0F/copyrightholder/
n16http://orcid.org/0000-0002-9368-1014#
n7http://orcid.org/0000-0002-7949-5362#
n21http://orcid.org/0000-0001-8782-4245#
n9http://hub.abes.fr/referentiel/springer/periodical/10620/articletypes/
bibohttp://purl.org/ontology/bibo/
n2http://hub.abes.fr/springer/periodical/10620/1994/volume_39/issue_12/B947C239FA9D2014E053120B220ACB0F/
n20http://hub.abes.fr/springer/periodical/10620/1994/volume_39/issue_12/B947C239FA9D2014E053120B220ACB0F/m/
rdachttp://rdaregistry.info/Elements/c/
hubhttp://hub.abes.fr/namespace/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
rdawhttp://rdaregistry.info/Elements/w/
n14http://hub.abes.fr/springer/periodical/10620/1994/volume_39/issue_12/B947C239FA9D2014E053120B220ACB0F/authorship/
n18http://hub.abes.fr/springer/periodical/10620/
xsdhhttp://www.w3.org/2001/XMLSchema#
n11http://hub.abes.fr/springer/periodical/10620/1994/volume_39/issue_12/B947C239FA9D2014E053120B220ACB0F/subject/
n10http://hub.abes.fr/referentiel/springer/articletypes/
Subject Item
n2:w
rdf:type
bibo:Article rdac:C10001
dcterms:isPartOf
n15:w
dcterms:subject
n11:crohnsdisease n11:fishoil
dcterms:title
Effects of new fish oil derivative on fatty acid phospholipid-membrane pattern in a group of Crohn's disease patients
rdaw:P10072
n20:web n20:print
vivo:relatedBy
n14:4 n14:7 n14:11 n14:6 n14:10 n14:9 n14:1 n14:2 n14:5 n14:3 n14:8
marcrel:aut
n7:person n2:barbaral n12:person n2:brignolac n2:migliolim n16:person n2:boschis n21:person n2:bellolic n2:camporesiep n2:desimoneg
dcterms:abstract
Abstract. Fish oil has been recently proposed as a possible effective treatment in inflammatory bowel disease (IBD); however, a lot of annoying side effects (ie, belching, halitosis, diarrhea, etc) affect patient compliance. We carried out a study of patient tolerance in a group of Crohn's disease (CD) patients with a new fish oil derivative consisting of 500-mg capsules of eicosapentaenoic-docosahexaenoic (EPA 40%-DHA 20%), a free fatty acid mixture (Purepa), and we also evaluated its incorporation into phospholipids, both in plasma and in red cell membranes. Five groups of 10 CD patients in remission received nine Purepa capsules daily in four different preparations (A: uncoated, B: coated, pH 5.5; C: coated, pH 5.5, 60 min time release; D: coated, pH 6.9) and 12 × 1-g capsules daily of a triglyceride preparation (Max-EPA, EPA 18%-DHA 10%), respectively. We coated three of the four Purepa preparations in order to delay the release of contents in an attempt to minimize the side effects. After six weeks of treatment, the group taking Purepa capsules, coated, pH 5.5, 60 min time release (group C) showed the best incorporation of EPA and DHA in red blood cell phospholipid membranes (EPA from 0.2 to 4.4%, DHA from 3.7 to 6.3%), and no side effects were registered, whereas in all other groups side effects were experienced in 50% or more of subjects. This new preparation will make it possible to treat patients for long periods.
hub:articleType
n9:intestinaldisordersinflammatoryboweldiseaseimmunologyandmicrobiology n10:originalpaper
hub:publisher-id
BF02087694
dcterms:dateCopyrighted
1994
dcterms:rightsHolder
n4:plenumpublishingcorporation
hub:isPartOfThisJournal
n18:w